The influence of TP53 mutation on the therapeutic effect of EGFR tyrosine kinase inhibitor and prognosis of EGFR mutant non-small cell lung cancer patients
10.3760/cma.j.issn.0253-3766.2020.01.012
- VernacularTitle: TP53突变对非小细胞肺癌表皮生长因子受体突变患者酪氨酸激酶抑制剂的治疗效果和预后影响
- Author:
Yibulayin XIAYIMAIERDAN
1
;
Peng SONG
;
Shugeng GAO
Author Information
1. Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China
- Publication Type:Journal Article
- Keywords:
Carcinoma, non-small-cell lung;
Tyrosine kinase inhibitors;
TP53;
Eepidermal growth factor receptor;
Prognosis
- From:
Chinese Journal of Oncology
2020;42(1):74-77
- CountryChina
- Language:Chinese
-
Abstract:
Gene mutations can impair the sensitivity of cancer cells to targeted drugs, and lead to individual differences of clinical therapeutic effects. Epidermal growth factor receptor (EGFR) mutation plays an important role in therapeutic decision-making. Furthermore, some co-existing gene mutations, such as TP53 mutation, can also affect the therapeutic effect and prognosis of patients. Whether EGFR mutation combined with TP53 mutation affects the sensitivity of lung cancer cells to tyrosine kinase inhibitor (TKI) and long-term prognosis of non-small cell lung cancer (NSCLC) patients is still unknown and has attracted more attentions. However, in the current clinical practice, TP53 mutation is not a key factor of therapeutic decision-making, so further studies are needed to clarify the impact of TP53 mutation (including each subtype) on the potential benefits of EGFR-targeted therapy of NSCLC.
